Ixazomib citrate EtOH - CAS 2026591-78-4

Ixazomib citrate, also known as MLN9708, is a prodrug of Ixazomib (MMLN-2238) . MLN9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN9708, compared with bortezomib, has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies.

Others

Others

2026509

C22H29BCl2N2O10

563.188

CCO.CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1

-20°C

Ice Packs

Small Compound